NasdaqCM:CPRXBiotechs
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Growth Strength And Positive Analyst Sentiment
Catalyst Pharmaceuticals (CPRX) has come onto investors’ radar after appearing on an “Affordable Growth” screen. The screen highlights a mix of double-digit earnings and revenue growth, solid profitability and a debt-free balance sheet.
See our latest analysis for Catalyst Pharmaceuticals.
At a share price of US$24.30, Catalyst Pharmaceuticals has seen a 14.25% 90 day share price return. The 1 year total shareholder return of 7.71% and very large 5 year total shareholder return suggest...